Clinical Trial Update: A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 trial of CP-945,598 to prevent weight regain in obese patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 3 | Status: TERMINATED